Objective: To investigate differences in region-specific gray matter (GM) damage between adults with pediatric-onset (PO) multiple sclerosis (MS) and adult-onset (AO) MS.
Methods: Twenty-four relapsing-remitting (RR) adults with POMS (mean age = 35 years, mean disease duration = 18.4 years) were compared to 23 age-matched (AOA, mean age = 33.9 years, mean disease duration = 2.4 years) and 24 disease-duration matched (AOD, mean age = 45.9 years, mean disease duration = 18.5 years) RRMS adults who developed MS after the age of 18. Three-dimensional-T1-weighted images were acquired on a 1.5 T MRI. Image analysis was conducted using voxel-based morphometry (Statistical Parametric Mapping 8).
Results: There were no regional GM atrophy differences between POMS and AODMS groups. No regional GM atrophy differences were found between POMS and AOAMS patients when disease duration was included as a covariate.
Conclusions: Regional GM differences were not found between POMS adults and MS controls matched for age or disease duration. Although of limited sample size, these findings suggest that there are no regional GM atrophy differences between RR POMS and AOMS.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1552-6569.2012.00775.x | DOI Listing |
Trials
January 2025
Department of Neurology, the First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China.
Background: Early neurological deterioration (END) is a critical determinant influencing the short-term prognosis of acute ischemic stroke (AIS) patients and is associated with increased mortality rates among hospitalized individuals. AIS frequently coexists with coronary heart disease (CHD), complicating treatment and leading to more severe symptoms and worse outcomes. Shared risk factors between CHD and AIS, especially elevated low-density lipoprotein cholesterol (LDL-C), contribute to atherosclerosis and inflammation, which worsen brain tissue damage.
View Article and Find Full Text PDFNutr Metab (Lond)
January 2025
Department of Sports Medicine, China Medical University, Taichung City, Taiwan.
Background: Intermittent fasting (IF) can be an effective dietary therapy for weight loss and improving cardiometabolic health. However, there is scant evidence regarding the role of IF on indicators of liver function, particularly in adults with metabolic disorders. Therefore, we performed a systematic review and meta-analysis to investigate the effects of IF on liver function in adults with metabolic disorders.
View Article and Find Full Text PDFBMC Pediatr
January 2025
Department of Pediatrics, Faculty of Medicine, Fayoum University, Fayoum, Egypt.
Background: Pediatric CNS infections have been identified as a global health problem, associated with an increased death rate and fatal consequences. Pentraxin 3 (PTX3) is an acute-phase mediator that increases in body fluids and plasma throughout inflammation. Our study was designed to assess the diagnostic and prognostic value of cerebrospinal fluid (CSF) PTX3 levels in pediatric patients with different central nervous system (CNS) infections.
View Article and Find Full Text PDFBMC Infect Dis
January 2025
Department of Infectious Diseases, School of Medicine, Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High Risk Behaviors, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Background: Reduced Bone Mineral Density (BMD) has been linked to Human Immunodeficiency Virus (HIV) infection and treatment. There is a lack of information regarding the osteoporosis status of middle-aged patients with HIV in Iran, despite the fact that Antiretroviral Therapy (ART) is widely accessible.
Objective: The purpose of this cross-sectional study was to assess the BMD status and low BMD risk factors in patients with HIV under ART living in Iran.
BMC Infect Dis
January 2025
Department of Microbiology Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka, Saliyapura Sri Lanka, 50008, Sri Lanka.
Background: Mucormycosis is an opportunistic fungal infection which is associated with poor prognosis. Only a few antifungals are available in the arsenal against mucormycosis. The global guidelines for diagnosing and managing mucormycosis recommend high doses of liposomal amphotericin B (LAmB) as the first-line treatment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!